Maze Therapeutics, Inc. (MAZE): Total Assets
$397.13M
As of 2025-12-31
$531.62M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $397.13M | +65.1% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $240.54M | n/a | 2026-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $397.13M | +65.1% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $404.27M | -14.9% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $415.90M | -24.2% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $416.89M | -16.8% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $448.37M | -27.9% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $351.53M | +4.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
Compare MAZE, SRRK, ALLO, SANA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗